<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240810061105&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240810061105&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 10 Aug 2024 10:11:06 +0000</lastbuilddate>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Heart failure and ischaemic heart disease: new challenges and opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 9;45(30):2681-2685. doi: 10.1093/eurheartj/ehae497.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39121015</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae497>10.1093/eurheartj/ehae497</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121015</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure and ischaemic heart disease: new challenges and opportunities</dc:title>
<dc:identifier>pmid:39121015</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae497</dc:identifier>
</item>
<item>
<title>Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115523/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 2:S0735-1097(24)07774-X. doi: 10.1016/j.jacc.2024.06.026. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115523/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39115523</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.026>10.1016/j.jacc.2024.06.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115523</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>João Sérgio Neves</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?</dc:title>
<dc:identifier>pmid:39115523</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.026</dc:identifier>
</item>
<item>
<title>Training of the adult congenital cardiac interventionalist: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115082/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae495. doi: 10.1093/eurheartj/ehae495. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115082/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39115082</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae495>10.1093/eurheartj/ehae495</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115082</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jamil Aboulhosn</dc:creator>
<dc:creator>Carlos Pedra</dc:creator>
<dc:creator>Eric Horlick</dc:creator>
<dc:creator>Teiji Akagi</dc:creator>
<dc:creator>Massimo Chessa</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Training of the adult congenital cardiac interventionalist: a call to action</dc:title>
<dc:identifier>pmid:39115082</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae495</dc:identifier>
</item>
<item>
<title>KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae476. doi: 10.1093/eurheartj/ehae476. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39115049</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae476>10.1093/eurheartj/ehae476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115049</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sahej Bains</dc:creator>
<dc:creator>Lucilla Giammarino</dc:creator>
<dc:creator>Saranda Nimani</dc:creator>
<dc:creator>Nicolo Alerni</dc:creator>
<dc:creator>David J Tester</dc:creator>
<dc:creator>C S John Kim</dc:creator>
<dc:creator>Nicolas Christoforou</dc:creator>
<dc:creator>Julien Louradour</dc:creator>
<dc:creator>András Horváth</dc:creator>
<dc:creator>Olgica Beslac</dc:creator>
<dc:creator>Miriam Barbieri</dc:creator>
<dc:creator>Lluis Matas</dc:creator>
<dc:creator>Thomas S Hof</dc:creator>
<dc:creator>Ruben Lopez</dc:creator>
<dc:creator>Stefanie Perez-Feliz</dc:creator>
<dc:creator>Chiara Parodi</dc:creator>
<dc:creator>Luisana G Garcia Casalta</dc:creator>
<dc:creator>Jacqulyn Jurgensen</dc:creator>
<dc:creator>Michael A Barry</dc:creator>
<dc:creator>Mariana Bego</dc:creator>
<dc:creator>Lisa Keyes</dc:creator>
<dc:creator>Jane Owens</dc:creator>
<dc:creator>Jason Pinkstaff</dc:creator>
<dc:creator>Gideon Koren</dc:creator>
<dc:creator>Manfred Zehender</dc:creator>
<dc:creator>Michael Brunner</dc:creator>
<dc:creator>Daniela Casoni</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Andreas Haeberlin</dc:creator>
<dc:creator>Gabriel Brooks</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Katja E Odening</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome</dc:title>
<dc:identifier>pmid:39115049</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae476</dc:identifier>
</item>
<item>
<title>Metabolites regulating chromatin accessibility: a piece of the puzzle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae468. doi: 10.1093/eurheartj/ehae468. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39115023</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae468>10.1093/eurheartj/ehae468</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115023</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolle Kränkel</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Metabolites regulating chromatin accessibility: a piece of the puzzle</dc:title>
<dc:identifier>pmid:39115023</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae468</dc:identifier>
</item>
<item>
<title>Stroke triggers an innate immune memory that drives cardiac dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39112562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01069-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39112562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39112562</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01069-z>10.1038/s41569-024-01069-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39112562</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Stroke triggers an innate immune memory that drives cardiac dysfunction</dc:title>
<dc:identifier>pmid:39112562</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01069-z</dc:identifier>
</item>
<item>
<title>Mechanisms and treatment of pulmonary arterial hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39112561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01064-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39112561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39112561</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01064-4>10.1038/s41569-024-01064-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39112561</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Hossein-Ardeschir Ghofrani</dc:creator>
<dc:creator>Mardi Gomberg-Maitland</dc:creator>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Friedrich Grimminger</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mechanisms and treatment of pulmonary arterial hypertension</dc:title>
<dc:identifier>pmid:39112561</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01064-4</dc:identifier>
</item>
<item>
<title>Active-Duty Sailor Develops PFO-Associated Decompression Sickness: Do Occupational Divers Warrant Alternative Cardiac Screening Standards?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>We report a case of an active-duty diver who developed severe decompression sickness with concomitant patent foramen ovale that was successfully closed contrary to standard guideline recommendations. This case should prompt evaluation of the role of cardiac screening in occupational divers, including tactical athletes, relative to recreational divers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):678-682. doi: 10.1016/j.jacc.2024.06.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We report a case of an active-duty diver who developed severe decompression sickness with concomitant patent foramen ovale that was successfully closed contrary to standard guideline recommendations. This case should prompt evaluation of the role of cardiac screening in occupational divers, including tactical athletes, relative to recreational divers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111976</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.010>10.1016/j.jacc.2024.06.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111976</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tarin C Phillips</dc:creator>
<dc:creator>W Rainey Johnson</dc:creator>
<dc:creator>Nitin L Rao</dc:creator>
<dc:creator>Caroline E Murphy</dc:creator>
<dc:creator>Robert M Gallagher</dc:creator>
<dc:creator>Sonya N Waters</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Active-Duty Sailor Develops PFO-Associated Decompression Sickness: Do Occupational Divers Warrant Alternative Cardiac Screening Standards?</dc:title>
<dc:identifier>pmid:39111976</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.010</dc:identifier>
</item>
<item>
<title>Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients With Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):675-677. doi: 10.1016/j.jacc.2024.04.066.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111975</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.066>10.1016/j.jacc.2024.04.066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111975</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:creator>Hannah K Gaggin</dc:creator>
<dc:creator>Olivier F Clerc</dc:creator>
<dc:creator>Shilpa Vijayakumar</dc:creator>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:creator>Rodney H Falk</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients With Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:39111975</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.066</dc:identifier>
</item>
<item>
<title>Ending Trans Fat-The First-Ever Global Elimination Program for a Noncommunicable Disease Risk Factor: JACC International</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>Industrially produced trans fat (iTFA) is a harmful compound created as a substitute for animal and saturated fats. Estimated to cause up to 500,000 deaths per year, it is replaceable. In 2018, Resolve to Save Lives, the World Health Organization (WHO), Global Health Advocacy Incubator, and NCD Alliance partnered to achieve global trans fat elimination. The WHO Director-General called for the elimination of trans fat by 2023 through best practice policies outlined in the WHO REPLACE package....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):663-674. doi: 10.1016/j.jacc.2024.04.067.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Industrially produced trans fat (iTFA) is a harmful compound created as a substitute for animal and saturated fats. Estimated to cause up to 500,000 deaths per year, it is replaceable. In 2018, Resolve to Save Lives, the World Health Organization (WHO), Global Health Advocacy Incubator, and NCD Alliance partnered to achieve global trans fat elimination. The WHO Director-General called for the elimination of trans fat by 2023 through best practice policies outlined in the WHO REPLACE package. Since the accelerated global efforts in 2018, 43 countries have adopted best practice regulations protecting an additional 3.2 billion people and building momentum toward global elimination. Current coverage will prevent 66% of deaths estimated to be caused each year by trans fat in foods. Despite producing and selling iTFA-free products in many countries, companies continue to sell iTFA-containing products in unregulated markets. Global incentives, accountability mechanisms, and regional policies will help achieve the elimination goal.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111974</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.067>10.1016/j.jacc.2024.04.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111974</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Lindsay Steele</dc:creator>
<dc:creator>Elizabeth Drummond</dc:creator>
<dc:creator>Chizuru Nishida</dc:creator>
<dc:creator>Rain Yamamoto</dc:creator>
<dc:creator>Francesco Branca</dc:creator>
<dc:creator>Cristina Parsons Perez</dc:creator>
<dc:creator>Lorena Allemandi</dc:creator>
<dc:creator>Liz Arnanz</dc:creator>
<dc:creator>Veronica Schoj</dc:creator>
<dc:creator>Hema S Khanchandani</dc:creator>
<dc:creator>Swati Bhardwaj</dc:creator>
<dc:creator>Renu Garg</dc:creator>
<dc:creator>Thomas R Frieden</dc:creator>
<dc:creator>Laura K Cobb</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ending Trans Fat-The First-Ever Global Elimination Program for a Noncommunicable Disease Risk Factor: JACC International</dc:title>
<dc:identifier>pmid:39111974</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.067</dc:identifier>
</item>
<item>
<title>Use of Feature Tracking to Predict Outcome in Epidemiologic Studies Using Cardiac Magnetic Resonance Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):660-662. doi: 10.1016/j.jacc.2024.05.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111973</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.052>10.1016/j.jacc.2024.05.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111973</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Marwick</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Feature Tracking to Predict Outcome in Epidemiologic Studies Using Cardiac Magnetic Resonance Imaging</dc:title>
<dc:identifier>pmid:39111973</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.052</dc:identifier>
</item>
<item>
<title>Myocardial Strain Measured by Cardiac Magnetic Resonance Predicts Cardiovascular Morbidity and Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111972/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the general population, LV strain metrics derived using CMR-FT in radial, circumferential, and longitudinal directions are strongly and independently predictive of heart failure, myocardial infarction, and stroke, but only GLS is independently predictive of death in an adult population cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):648-659. doi: 10.1016/j.jacc.2024.05.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial strain using cardiac magnetic resonance (CMR) is a sensitive marker for predicting adverse outcomes in many cardiac disease states, but the prognostic value in the general population has not been studied conclusively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to assess the independent prognostic value of CMR feature tracking (FT)-derived LV global longitudinal (GLS), circumferential (GCS), and radial strain (GRS) metrics in predicting adverse outcomes (heart failure, myocardial infarction, stroke, and death).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants from the UK Biobank population imaging study were included. Univariable and multivariable Cox models were used for each outcome and each strain marker (GLS, GCS, GRS) separately. The multivariable models were tested with adjustment for prognostically important clinical features and conventional global LV imaging markers relevant for each outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 45,700 participants were included in the study (average age 65 ± 8 years), with a median follow-up period of 3 years. All univariable and multivariable models demonstrated that lower absolute GLS, GCS, and GRS were associated with increased incidence of heart failure, myocardial infarction, stroke, and death. All strain markers were independent predictors (incrementally above some respective conventional LV imaging markers) for the morbidity outcomes, but only GLS predicted death independently: (HR: 1.18; 95% CI: 1.07-1.30).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the general population, LV strain metrics derived using CMR-FT in radial, circumferential, and longitudinal directions are strongly and independently predictive of heart failure, myocardial infarction, and stroke, but only GLS is independently predictive of death in an adult population cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111972</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.050>10.1016/j.jacc.2024.05.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111972</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sucharitha Chadalavada</dc:creator>
<dc:creator>Kenneth Fung</dc:creator>
<dc:creator>Elisa Rauseo</dc:creator>
<dc:creator>Aaron M Lee</dc:creator>
<dc:creator>Mohammed Y Khanji</dc:creator>
<dc:creator>Alborz Amir-Khalili</dc:creator>
<dc:creator>Jose Paiva</dc:creator>
<dc:creator>Hafiz Naderi</dc:creator>
<dc:creator>Shantanu Banik</dc:creator>
<dc:creator>Mihaela Chirvasa</dc:creator>
<dc:creator>Magnus T Jensen</dc:creator>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Myocardial Strain Measured by Cardiac Magnetic Resonance Predicts Cardiovascular Morbidity and Death</dc:title>
<dc:identifier>pmid:39111972</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.050</dc:identifier>
</item>
<item>
<title>Ventricles Under Stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111971/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):645-647. doi: 10.1016/j.jacc.2024.05.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111971/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111971</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.053>10.1016/j.jacc.2024.05.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111971</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert F Wilson</dc:creator>
<dc:creator>Demetris Yannopoulos</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricles Under Stress</dc:title>
<dc:identifier>pmid:39111971</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.053</dc:identifier>
</item>
<item>
<title>Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients With Valvular Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TAVR results in significant reductions in systolic LVWS acutely. MC results in significant reductions in diastolic LVWS. Higher baseline systolic LVWS in TAVR is associated with shorter 6MWT suggesting that in AS, LVWS may be a useful marker of early decompensation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):635-644. doi: 10.1016/j.jacc.2024.04.068.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortic stenosis (AS) and mitral regurgitation (MR) result in different patterns of left ventricular remodeling and hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We characterized left ventricular wall stress (LVWS) profiles in pressure and volume-overloaded systems, examined the relationship between baseline LVWS and cardiac remodeling, and assessed the acute effects of valve intervention on LVWS using invasive pressures combined with cardiac magnetic resonance (CMR) imaging measures of left ventricular volumes/mass.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 47 patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) and 15 patients with severe MR undergoing MitraClip (MC) underwent a 6-minute walk test (6MWT), transthoracic echocardiogram, and CMR before their procedures. Catheters in the left ventricle were used to record hemodynamic changes before and after valve/clip deployment. This was integrated with CMR data to calculate LVWS before and after intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The TAVR group demonstrated significant reductions in systolic LVWS post procedure (median 24.7 Pa [IQR: 14 Pa] pre vs median 17.3 Pa [IQR: 12 Pa] post; P &lt; 0.001). The MC group demonstrated significant reductions in diastolic LVWS (median 6.4 Pa [IQR: 5 Pa] pre vs median 4.3 Pa [IQR: 4.1 Pa] post; P = 0.021) with no significant change in systolic LVWS (30.6 ±1.61 pre vs 33 ±2.47 Pa post; P = 0.16). There was an inverse correlation between baseline systolic LVWS and 6MWT in the TAVR group (r = -0.31; P = 0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TAVR results in significant reductions in systolic LVWS acutely. MC results in significant reductions in diastolic LVWS. Higher baseline systolic LVWS in TAVR is associated with shorter 6MWT suggesting that in AS, LVWS may be a useful marker of early decompensation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111970</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.068>10.1016/j.jacc.2024.04.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111970</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stavroula Papapostolou</dc:creator>
<dc:creator>John Kearns</dc:creator>
<dc:creator>Benedict T Costello</dc:creator>
<dc:creator>Jessica O'Brien</dc:creator>
<dc:creator>Sarah J Gutman</dc:creator>
<dc:creator>Shane Nanayakarra</dc:creator>
<dc:creator>David Kaye</dc:creator>
<dc:creator>Antony Walton</dc:creator>
<dc:creator>James Hare</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>Andrew J Taylor</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients With Valvular Heart Disease</dc:title>
<dc:identifier>pmid:39111970</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.068</dc:identifier>
</item>
<item>
<title>Getting to Transplant Should Not Be the Goal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111969/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):633-634. doi: 10.1016/j.jacc.2024.06.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111969</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.009>10.1016/j.jacc.2024.06.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111969</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>David L S Morales</dc:creator>
<dc:creator>Benjamin S Mantell</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Getting to Transplant Should Not Be the Goal</dc:title>
<dc:identifier>pmid:39111969</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.009</dc:identifier>
</item>
<item>
<title>Contemporary Pediatric Heart Transplant Waitlist Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The 2016 allocation revisions were not independently associated with the decline in pediatric HT waitlist mortality. The 3-tier classification system fails to adequately capture patient-specific risks. A more flexible allocation system that accurately reflects patient-specific risks and considers transplant benefit is urgently needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):620-632. doi: 10.1016/j.jacc.2024.05.049.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In 2016, the United Network for Organ Sharing revised its pediatric heart transplant (HT) allocation policy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether the 2016 revisions are associated with reduced waitlist mortality and capture patient-specific risks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Children listed for HT from 1999 to 2023 were identified using Organ Procurement and Transplantation Network data and grouped into 3 eras (era 1: 1999-2006; era 2: 2006-2016; era 3: 2016-2023) based on when the United Network for Organ Sharing implemented allocation changes. Fine-Gray competing risks modeling was used to identify factors associated with death or delisting for deterioration. Fixed-effects analysis was used to determine whether allocation changes were associated with mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Waitlist mortality declined 8 percentage points (PP) across eras (21%, 17%, and 13%, respectively; P &lt; 0.01). At listing, era 3 children were less sick than era 1 children, with 6 PP less ECMO use (P &lt; 0.01), 11 PP less ventilator use (P &lt; 0.01), and 1 PP less dialysis use (P &lt; 0.01). Ventricular assist device (VAD) use was 13 PP higher, and VAD mortality decreased 9 PP (P &lt; 0.01). Non-White mortality declined 10 PP (P &lt; 0.01). ABO-incompatible listings increased 27 PP, and blood group O infant mortality decreased 13 PP (P &lt; 0.01). In multivariable analyses, the 2016 revisions were not associated with lower waitlist mortality, whereas VAD use (in era 3), ABO-incompatible transplant, improved patient selection, and narrowing racial disparities were. Match-run analyses demonstrated poor correlation between individual waitlist mortality risk and the match-run order.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 2016 allocation revisions were not independently associated with the decline in pediatric HT waitlist mortality. The 3-tier classification system fails to adequately capture patient-specific risks. A more flexible allocation system that accurately reflects patient-specific risks and considers transplant benefit is urgently needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111968</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.049>10.1016/j.jacc.2024.05.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111968</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Alyssa Power</dc:creator>
<dc:creator>Kurt R Sweat</dc:creator>
<dc:creator>Alvin Roth</dc:creator>
<dc:creator>John C Dykes</dc:creator>
<dc:creator>Beth Kaufman</dc:creator>
<dc:creator>Michael Ma</dc:creator>
<dc:creator>Sharon Chen</dc:creator>
<dc:creator>Seth A Hollander</dc:creator>
<dc:creator>Elizabeth Profita</dc:creator>
<dc:creator>David N Rosenthal</dc:creator>
<dc:creator>Lynsey Barkoff</dc:creator>
<dc:creator>Chiu-Yu Chen</dc:creator>
<dc:creator>Ryan R Davies</dc:creator>
<dc:creator>Christopher S Almond</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Contemporary Pediatric Heart Transplant Waitlist Mortality</dc:title>
<dc:identifier>pmid:39111968</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.049</dc:identifier>
</item>
<item>
<title>A Bright Future for Tricuspid Repair Success</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):617-619. doi: 10.1016/j.jacc.2024.05.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111967</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.051>10.1016/j.jacc.2024.05.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111967</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Bright Future for Tricuspid Repair Success</dc:title>
<dc:identifier>pmid:39111967</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.051</dc:identifier>
</item>
<item>
<title>H5N1 influenza: Urgent questions and directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>H5N1 is an avian influenza virus that causes respiratory disease in birds and several land and sea mammals. The recent outbreak in the United States, including infection of dairy workers, has increased the concern around potential transmission and spread. We asked virologists, epidemiologists, and public health experts what the most urgent questions and action points are at this stage of the outbreak.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 26:S0092-8674(24)00784-0. doi: 10.1016/j.cell.2024.07.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">H5N1 is an avian influenza virus that causes respiratory disease in birds and several land and sea mammals. The recent outbreak in the United States, including infection of dairy workers, has increased the concern around potential transmission and spread. We asked virologists, epidemiologists, and public health experts what the most urgent questions and action points are at this stage of the outbreak.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39111311</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.024>10.1016/j.cell.2024.07.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111311</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Gonazalo Moratorio</dc:creator>
<dc:creator>Sannula Kesavardhana</dc:creator>
<dc:creator>Seema S Lakdawala</dc:creator>
<dc:creator>Leo Poon</dc:creator>
<dc:creator>Michael Worobey</dc:creator>
<dc:creator>Jennifer Nuzzo</dc:creator>
<dc:creator>Shuo Su</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>H5N1 influenza: Urgent questions and directions</dc:title>
<dc:identifier>pmid:39111311</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.024</dc:identifier>
</item>
<item>
<title>Evaluating Pregnancy Safety During Cardiology Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7:e242294. doi: 10.1001/jamacardio.2024.2294. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39110472</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11307157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">PMC11307157</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2294>10.1001/jamacardio.2024.2294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110472</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Leila Haghighat</dc:creator>
<dc:creator>Shadi Kalantarian</dc:creator>
<dc:creator>Jacqueline T DesJardin</dc:creator>
<dc:creator>Cara N Pellegrini</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Evaluating Pregnancy Safety During Cardiology Training</dc:title>
<dc:identifier>pmid:39110472</dc:identifier>
<dc:identifier>pmc:PMC11307157</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2294</dc:identifier>
</item>
<item>
<title>Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management. Interventions to further protect people in the highest risk first month after infarction are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7:e242356. doi: 10.1001/jamacardio.2024.2356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI. Whether the prognosis in such patients has changed over time has not been examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the rate of sudden death/resuscitated cardiac arrest (RCA) after AMI in the PARADISE-MI and VALIANT trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of multicenter randomized clinical trials enrolling patients after AMI. In the primary analysis, the VALIANT cohort was restricted to patients with "PARADISE-MI-like" characteristics (eg, at least 1 augmenting risk factor and no history of heart failure). The baseline characteristics of people in both trials were compared. The VALIANT trial enrolled from December 1998 to June 2001, and the PARADISE-MI trial enrolled between December 2016, and March 2020. The median follow-up in the VALIANT and PARADISE-MI trials was 24.7 and 22 months, respectively. People with AMI, complicated by pulmonary congestion and/or left ventricular dysfunction, were included in the analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Sudden death after AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5661 patients were included in the PARADISE-MI cohort (mean [SD] age, 63.7 [11.5] years; 4298 male [75.9%]), 9617 were included in the VALIANT (PARADISE-MI-like) cohort (mean [SD] age, 66.1 [11.5] years; 6504 male [67.6%]), and 14 703 patients were included in the VALIANT (total) cohort (mean [SD] age, 64.8 [11.8] years; 10 133 male [68.9%]). In the PARADISE-MI-like cohort of the VALIANT trial, 707 of 9617 participants (7.4%) experienced sudden death/RCA. A total of 148 of 5661 people (2.6%) in the PARADISE-MI trial experienced sudden death/RCA. Sudden death rates were highest in the first month after infarction in both trials: 19.3 (95% CI, 16.4-22.6) per 100 person-years in the VALIANT trial and 9.5 (95% CI, 7.0-12.7) per 100 person-years in the PARADISE-MI trial, and these rates declined steadily thereafter. Compared with the VALIANT cohort, people in the PARADISE-MI trial were more often treated with percutaneous coronary intervention for their qualifying AMI and received a β-blocker, statin, and mineralocorticoid receptor antagonist more frequently.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management. Interventions to further protect people in the highest risk first month after infarction are needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02924727.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39110471</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11307160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">PMC11307160</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2356>10.1001/jamacardio.2024.2356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110471</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>James P Curtain</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Doug L Mann</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Peter V Finn</dc:creator>
<dc:creator>Alberto Fernandez</dc:creator>
<dc:creator>Karola S Jering</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials</dc:title>
<dc:identifier>pmid:39110471</dc:identifier>
<dc:identifier>pmc:PMC11307160</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2356</dc:identifier>
</item>
<item>
<title>Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39110452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240810061105&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 7. doi: 10.1001/jamacardio.2024.2362. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39110452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240810061105&v=2.18.0.post9+e462414">39110452</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2362>10.1001/jamacardio.2024.2362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39110452</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication</dc:title>
<dc:identifier>pmid:39110452</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2362</dc:identifier>
</item>





























</channel>
</rss>